ArticleDiscover oncology2025
miR-130a-5p/TFPI2 axis promotes invasion of hepatocellular carcinoma by altering epithelial-to-mesenchymal transition.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TFPI2 in tumor metastasis: a double-edged sword with clinical implications.Cancer biology & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMicroRNAs (miRNAs), particularly miR-130a-5p, play pivotal roles in the tumorigenesis and progression of hepatocellular carcinoma (HCC) by participating in diverse biological processes. The objective of this study was to elucidate the mechanistic basis by which miR-130a-5p regulates the expression of tissue factor pathway inhibitor-2 (TFPI2) and to demonstrate the subsequent impact of the miR-130a-5p/TFPI2 axis on HCC invasion.
methodsExpression levels of miR-130a-5p and TFPI2 were quantified in HepG2 cell lines using quantitative real-time PCR (qRT-PCR). Western blot and qRT-PCR were employed to assess the expression of TFPI2 and epithelial-to-mesenchymal transition (EMT)-related proteins in both cancer cells and tissues. miR-130a-5p knockdown and TFPI2 overexpression were achieved through transfection of HepG2 cells with short hairpin RNA (shRNA) and synthetic overexpression plasmids, respectively. A dual luciferase reporter assay was conducted to verify the binding of miR-130a-5p to TFPI2. Migration and invasion capabilities of cancer cells were evaluated using Transwell migration and invasion assays. A mouse xenograft tumor model was established to investigate tumor growth in vivo. Immunohistochemical (IHC) staining was utilized to examine the expression of EMT-related proteins in tumor tissues.
resultsThe dual-luciferase reporter assay confirmed that miR-130a-5p binds to the 3' untranslated region (3'UTR) of TFPI2 mRNA, inhibiting its luciferase activity. Western blot analysis revealed that miR-130a-5p negatively regulates TFPI2 protein expression and promotes EMT molecular events by targeting TFPI2 in HCC cells. Transwell assays demonstrated that downregulation of miR-130a-5p and upregulation of TFPI2 inhibited the migration and invasion abilities of HCC cells in vitro. Silencing of miR-130a-5p was found to retard the growth of HCC xenografts in vivo, decrease TFPI2 expression, and alter the EMT process.
conclusionsmiR-130a-5p binds to TFPI2 mRNA and promotes HCC cell migration, invasion, and xenograft tumor growth by regulating the EMT process. These findings suggest that the miR-130a-5p/TFPI2 axis may represent a promising therapeutic target for the treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.